Camille Nelson Kotton

Camille Nelson Kotton MD is the clinical director of the Transplant Infectious Disease and Compromised Host Program at the Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. She also directs the outpatient Transplant Infectious Disease Clinic. She graduated from the University of Chicago School of Medicine, and did internal medicine training at The Hospital of the University of Pennsylvania followed by an infectious diseases fellowship at the Massachusetts General Hospital and Brigham and Women’s Hospital. Her clinical interests include donor-derived infections, zoonoses, and travel and tropical medicine in the transplant setting.

She is the current chair elect of The Infectious Disease Community of Practice of The American Society of Transplantation. She was the president of The Transplant Infectious Disease Section of The Transplantation Society from 2007-2013. Highlights of her time as president include the development of international guidelines on CMV management after solid organ transplant, published in Transplantation (2010); a similar follow-up meeting was held in October 2012. She has also contributed significantly to a meeting on management of tuberculosis issues in organ donors, recently published in the American Journal of Transplantation. In addition, she organized and led three international Transplant Infectious Disease meetings (Vancouver, 2010; Glasgow, 2011; Berlin, 2012; Vienna, 2013), and organized an international group of experts on the topic of transplant infectious disease in composite tissue allografts, for which they are actively developing guidelines for clinical management.

Speaker disclosure: All faculty and planners participating in this education program sponsored by AST are expected to disclose to the program audience any/all relevant financial relationships related to the content of their presentation(s) that may present a conflict of interest. Camille Kotton reported the following relationships which were evaluated by the AST Conflict of Interest Committee and it was determined there was no conflict of interest.

Consultant: Astellas, Cellestis, Merck, Oxford Immunotec, Roche Diagnostics